Alnylam Pharmaceuticals, Inc.

Alnylam Pharmaceuticals, Inc. is an American biopharmaceutical company focused on the discovery, development, and commercialization of RNA interference (RNAi) therapeutics. The company's mission is to translate the promise of RNAi into a new class of transformative medicines for people with rare and prevalent diseases. Founded in 2002, Alnylam Pharmaceuticals is headquartered in Cambridge, Massachusetts, U.S..

Alnylam has pioneered RNAi therapeutics, an innovative approach to gene silencing that targets the genetic causes of disease. Their portfolio of approved RNAi therapeutics includes ONPATTRO (patisiran), AMVUTTRA (vutrisiran), GIVLAARI (givosiran), and OXLUMO (lumasiran). Additionally, Leqvio (inclisiran) is commercialized by their partner Novartis, and Qfitlia is commercialized by Sanofi. The company's robust pipeline of investigational RNAi therapeutics is focused on diseases with high unmet medical need across various therapeutic areas, including genetic medicines, cardio-metabolic diseases, and hepatic infectious diseases.

Led by CEO Yvonne Greenstreet, who was appointed in January 2022, Alnylam Pharmaceuticals achieved a significant milestone in Q1 2026, reporting over $1 billion in quarterly net product revenues for the first time, largely driven by strong demand for AMVUTTRA, particularly in ATTR cardiomyopathy. The company reiterated its full-year 2026 guidance, projecting total net product revenues between $4.9 billion and $5.3 billion. Alnylam continues to advance a deep pipeline with over 25 active clinical programs, with several key clinical readouts anticipated in the second half of 2026, including the initiation of a Phase 1 trial for ALN-2232 for obesity and weight management.